Skip to content
Friday 7 August 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE
MorningWire

European business, markets and politics

FTSE 100
10,901.09
+0.31%
DAX
26,319.45
+0.69%
CAC 40
8,714.93
+0.17%
STOXX 50
6,523.86
+0.33%
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
More
GermanyFranceBankingAIEnergyFintechPropertyCapital Markets
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
  • DE

GSK

  • GSK and Astrazeneca shares slump as Trump vows drug price cut

    May 12, 2025

    GSK and Astrazeneca shares fall as Trump announces drug price cuts in a new executive order.

  • FTSE 100’s record run ends as pharma stocks slide on new Trump appointment 

    May 7, 2025

    The FTSE 100’s record run came to an end on Wednesday as pharma stocks slumped on the back of a controversial US regulatory appointment.  The blue-chip index spent the entire session in the red and closed off 0.4 per cent. Drugmakers GSK and Astrazeneca were among the top fallers, at nearly five per cent and [...]

  • GSK shares rise as FTSE 100 giant ‘well positioned’ for pharma tariffs

    April 30, 2025

    British drugmaker GSK insisted it was “well positioned” to respond to the impact of sector-specific tariffs amid widespread speculation President Donald Trump is set to target pharmaceutical imports with his tariff agenda. Trump voiced his desire to slap tariffs on pharma products in the “not too distant future”. He previously said: “We don’t make our [...]

  • As FTSE 100 pharma firms wait for a tariffs decision, what would drugs levies mean for consumers?

    April 22, 2025

    For FTSE 100 businesses navigating the shifting sands of Trump’s trade war, the uncertainty surrounding the tariffs has been almost as painful as the stock market shocks.  The pharmaceutical industry has been left in a particularly agonising limbo: free, for now, from the 10 per cent baseline import tax, but the US President keeps making [...]

  • Government scrambles to swerve Trump pharma tariffs

    April 16, 2025

    A race against time is underway to shield the UK pharmaceutical sector from potentially swinging Trump tariffs on imported drugs.  As it stands, there is an exemption for pharmaceuticals on the baseline 10 per cent tariffs for goods coming into the US.  However, President Trump has warned that there will be tariffs on imported pharma [...]

  • FTSE 100 slumps as EU and China launch retaliatory tariffs against US

    April 9, 2025

    The FTSE 100 closed in the red on Wednesday, reversing gains made at the start of the week. The blue-chip index was off 2.9 per cent. Pharma stocks drove losses on the back of fresh tariff threats from President Donald Trump. Astrazeneca closed off seven per cent and GSK 5.7 per cent. Lenders also suffered [...]

  • JD Sports, Dr Martens and miners: UK stocks hit by Trump tariffs

    April 3, 2025

    UK markets have been pummelled by US president Donald Trump’s newly-introduced tariffs, with JD Sports and miners hit particularly hard on the FTSE 100. JD Sports has been pushing a rapid expansion into the US, which is now its largest region by revenue, but is set to be hit by the 10 per cent tariff [...]

  • FTSE 100 pharma giants GSK and Astrazeneca appear to swerve Trump tariffs

    April 3, 2025

    FTSE 100 pharma giants GSK and Astrazeneca may have escaped the worst of US President Donald Trump’s tariffs, according to a City broker. Pharmaceutical goods appear to be exempt from higher-rate tariffs introduced by President Trump in his Rose Garden ‘Liberation Day’ address on Wednesday, but there is still uncertainty about the impact on the [...]

  • Mark Kleinman: Football watchdog search approaches injury time

    March 6, 2025

    Mark Kleinman is Sky News’ City Editor and the man who gets the Square Mile talking in his weekly Morning Wire column. Today, he tackles the football watchdog search, big pay at GSK and CityFibre’s M&A warchest Football watchdog search approaches final whistle They think it’s all over. To paraphrase the immortal line of Kenneth Wolstenholme, the 1966 World [...]

  • FTSE 100 giant GSK eyes more than £40bn in sales by 2031

    February 5, 2025

    Pharmaceutical giant GSK has hiked its 2031 sales forecast to more than £40bn, up from £38bn, after reporting better than forecast fourth quarter earnings. The London-listed pharma giant reported core earnings per share of 23.2p for the quarter, a drop of around 20 per cent year-on-year. However, this was greater than the 19p that analysts [...]

Posts pagination

  • Previous
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • …
  • Page 22
  • Next

Trending Articles

  • Revolut founder’s wealth set to balloon amid talks of share award at $500bn valuation

  • Rupert Lowe axes pensions triple lock and pledges tax cuts in economic plan

  • WPP slashes jobs as revenue continues to fall

  • Liverpool owners tipped to sell – but not to Amazon boss Bezos – by former CEO

  • As it happened: Stocks rise as oil fluctuates after Red Sea attack; US-Iran deal ‘being circulated’

MorningWire

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • Europe
  • UK & Ireland

Business

  • Markets
  • Banking
  • Technology
  • Energy
  • Property
  • Fintech

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About Morning Wire
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 Morning Wire Ltd · Published by Morning Wire Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook